The United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Regeneus' (RGS) Progenza, providing commercial rights in the U.S. through to 2032. Progenza is the company's lead cell therapy technology platform being developed for the treatment of osteoarthritis and other musculoskeletal diseases. Regeneus is in advanced negotiations with potential clinical licensees of Progenza for Japan.
